Naltrexone

"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Descriptor ID	D009271
MeSH Number(s)	D03.132.577.249.706.550 D03.605.497.750.550 D03.633.400.686.750.550 D04.615.723.795.706.550
Concept/Terms	Naltrexone Naltrexone Celupan Celupan Trexan Trexan Naltrexone Hydrochloride Naltrexone Hydrochloride Hydrochloride, Naltrexone ReVia ReVia Nemexin Nalorex Antaxone Antaxone EN-1639A EN-1639A EN 1639A EN1639A

Below are MeSH descriptors whose meaning is more general than "Naltrexone".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Opiate Alkaloids [D03.132.577]
Morphinans [D03.132.577.249]
Naloxone [D03.132.577.249.706]
Naltrexone [D03.132.577.249.706.550]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Morphinans [D03.605.497]
Naloxone [D03.605.497.750]
Naltrexone [D03.605.497.750.550]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 4 or More Rings [D03.633.400]
Morphinans [D03.633.400.686]
Naloxone [D03.633.400.686.750]
Naltrexone [D03.633.400.686.750.550]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Phenanthrenes [D04.615.723]
Morphinans [D04.615.723.795]
Naloxone [D04.615.723.795.706]
Naltrexone [D04.615.723.795.706.550]

Below are MeSH descriptors whose meaning is related to "Naltrexone".

Below are MeSH descriptors whose meaning is more specific than "Naltrexone".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.

Bar chart showing 24 publications over 18 distinct years, with a maximum of 3 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	0	1	1
1998	1	0	1
2000	1	0	1
2002	2	0	2
2004	1	0	1
2008	1	1	2
2010	0	1	1
2011	1	2	3
2012	0	1	1
2013	0	1	1
2014	0	2	2
2015	1	0	1
2019	1	0	1
2020	0	1	1
2022	0	1	1
2023	0	1	1
2024	1	1	2

Below are the most recent publications written about "Naltrexone" by people in Profiles.

Pramar YV. Microbiological Stability of Allopurinol, Clindamycin Hydrochloride, Naltrexone Hydrochloride, Spironolactone and Ursodiol Oral Liquids Compounded in PCCA Base, SuspendIt?. Int J Pharm Compd. 2024 Jul-Aug; 28(4):316-320.

View in: PubMed
Luo SX, Feaster DJ, Liu Y, Balise RR, Hu MC, Bouzoubaa L, Odom GJ, Brandt L, Pan Y, Hser YI, VanVeldhuisen P, Castillo F, Calderon AR, Rotrosen J, Saxon AJ, Weiss RD, Wall M, Nunes EV. Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA Psychiatry. 2024 Jan 01; 81(1):45-56.

View in: PubMed
Brandt L, Hu MC, Liu Y, Castillo F, Odom GJ, Balise RR, Feaster DJ, Nunes EV, Luo SX. Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder. Am J Psychiatry. 2023 05 01; 180(5):386-394.

View in: PubMed
El Hayek SA, Shatila MA, Adnan JA, Geagea LE, Kobeissy F, Talih FR. Is there a therapeutic potential in combining bupropion and naltrexone in schizophrenia? Expert Rev Neurother. 2022 Sep; 22(9):737-749.

View in: PubMed
Richards VL, Sajdeya R, Villalba K, Wang Y, Bryant V, Brumback B, Bryant K, Hahn JA, Cook RL. Secondary Analysis of a Randomized Clinical Trial of Naltrexone Among Women Living With HIV: Correlations Between Reductions in Self-Reported Alcohol Use and Changes in Phosphatidylethanol. Alcohol Clin Exp Res. 2021 01; 45(1):174-180.

View in: PubMed
Pramar YV, Mandal TK, Bostanian LA, Nguyen AT, Morris TC, Graves RA. Physicochemical Stability of Compounded Naltrexone Hydrochloride Solutions in PCCA Base SuspendIt. Int J Pharm Compd. 2019 Mar-Apr; 23(2):157-162.

View in: PubMed
Bress A, Kittles R, Wing C, Hooker SE, King A. Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. Pharmacogenet Genomics. 2015 Jun; 25(6):305-12.

View in: PubMed
Hwa LS, Shimamoto A, Kayyali T, Norman KJ, Valentino RJ, DeBold JF, Miczek KA. Dissociation of ?-opioid receptor and CRF-R1 antagonist effects on escalated ethanol consumption and mPFC serotonin in C57BL/6J mice. Addict Biol. 2016 Jan; 21(1):111-24.

View in: PubMed
Taylor AM, Roberts KW, Pradhan AA, Akbari HA, Walwyn W, Lutfy K, Carroll FI, Cahill CM, Evans CJ. Anti-nociception mediated by a ? opioid receptor agonist is blocked by a d receptor agonist. Br J Pharmacol. 2015 Jan; 172(2):691-703.

View in: PubMed
Nie Y, Ferrini MG, Liu Y, Anghel A, Paez Espinosa EV, Stuart RC, Lutfy K, Nillni EA, Friedman TC. Morphine treatment selectively regulates expression of rat pituitary POMC and the prohormone convertases PC1/3 and PC2. Peptides. 2013 Sep; 47:99-109.

View in: PubMed

People

Explore

Similar Concepts

Top Journals